Marker Therapeutics Reports Promising Phase 1 Lymphoma Trial of MT-601 Responses

August 26, 2025

DENVER, Colo., Aug 26, 2025 (247marketnews.com)- Marker Therapeutics (NASDAQ:MRKR) reported encouraging interim results from its ongoing Phase 1 APOLLO study of MT-601, a novel Multi-Antigen Recognizing T cell (MAR-T) therapy for relapsed B cell lymphoma.

Among Non-Hodgkin Lymphoma (NHL) patients evaluated, 66% achieved an objective response, and 50% reached complete response (CR). These patients were heavily pre-treated, with a median of five prior therapies, including CAR-T and bispecific antibody treatments. Responses showed early durability, with several patients maintaining remission for over six months and three beyond one year.

The study, which includes patients who relapsed after or were ineligible for anti-CD19 CAR-T cell therapy, also demonstrated a favorable safety profile. No dose-limiting toxicities (DLTs) or immune-effector cell associated neurotoxicity syndrome (ICANS) were observed in the dose escalation cohort (100×10⁶ to 400×10⁶ cells).

The dose expansion phase will focus on patients with Diffuse Large B Cell Lymphoma (DLBCL) at the maximum pre-specified dose. Marker’s CEO, Dr. Juan Vera, noted that the study data “underscore the potential of MT-601 in heavily pre-treated patients with lymphoma,” particularly those who progress after CAR-T.

With 78% response rate also seen in Hodgkin Lymphoma patients, MT-601 could represent a significant advance in treatment-resistant lymphomas across multiple subtypes.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (MRKR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.